Standard Family Office’s ResMed RMD Stock Holding History

Standard Family Office’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-288	Closed	-$63K	–	358
2022 Q3	$63K	Buy	+288	New	+$65.6K	0.03%	107
2021 Q3	–	Sell	-5,193	Closed	-$1.28M	–	431
2021 Q2	$1.28M	Buy	5,193 +4,634	+829%	+$974K	0.27%	30
2021 Q1	$108K	Buy	559 +1	+0.2%	+$201	0.03%	195
2020 Q4	$119K	Buy	+558	New	+$111K	0.03%	174

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Standard Family Office's RMD Position: Q4 2022 in Review

Standard Family Office sold out of ResMed (RMD) in Q4 2022, closing a stake of 288 shares — an estimated $63K sold.

Standard Family Office first reported a position in RMD in Q4 2020 and held it in 4 quarters. The position peaked at $1.28M in Q2 2021. 731 funds tracked by Wall St. Rank hold RMD as of Q4 2022.

Standard Family Office reported no remaining ResMed position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 288 ResMed shares in Q4 2022, an estimated $63K.
Standard Family Office first reported a position in ResMed in Q4 2020 and held it in 4 quarters.
Standard Family Office's ResMed position peaked at $1.28M in Q2 2021.
731 funds tracked by Wall St. Rank held ResMed as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.